Thrombosis
About the Disease
Complement Hyperactivation, Angiopathic Thrombosis, and Protein-Losing Enteropathy, also known as chaple, is related to blood group, cromer system and protein-losing enteropathy. An important gene associated with Complement Hyperactivation, Angiopathic Thrombosis, and Protein-Losing Enteropathy is CD55 (CD55 Molecule (Cromer Blood Group)). The drugs Dabigatran and Norethisterone have been mentioned in the context of this disorder. Affiliated tissues include liver, whole blood and endothelial, and related phenotypes are thrombocytosis and hepatomegaly
Common Targets
P5755 | G4780 | G51363 | G4072 | G2150 | G5624 | Heat shock protein 90 (nonspecified subtype) | P5760 | G3709 | G7057 | G5650 | Serine/threonine-protein kinase (PAK) (nonspecified subtype) | G5465 | Prostanoid Receptor (nonspecified subtype) | Diacylglycerol Acyltransferase (DGAT) (nonspecified subtype) | Prostaglandin EP Receptor (nonspecified subtype) | G7450 | G5196 | G5550 | Tyrosine-Protein Kinases Src (nonspecified subtype) | G2158 | G23569 | G3738 | G5028 | cAMP Phosphodiesterase (nonspecified subtype) | G1845 | G9942 | Protein kinase C (nonspecified subtype) | G5879 | G139760 | G6548 | Protein Kinase B (PKB/Akt) (nonspecified subtype) | Phosphatidylinositol 3-kinase (PI3K) (nonspecified subtype) | G440 | P18508 | G148 | G5023 | G4804 | G10800 | Calcium channel (nonspecified subtype) | G558 | G3710 | G3958 | G2280 | G79054 | G58508 | G59272 | G6768 | G2475 | G5802 | G2162 | G2053 | G2864 | G84876 | G4128 | G3827 | G407010 | G1950 | G3350 | G5321 | G5468 | G5733 | Phosphodiesterase 1 (PDE1) (nonspecified subtype) | G1268 | Cyclophilins (nonspecified subtype) | Alpha-2 Adrenergic receptors (nonspecified subtype) | G151 | G6530 | G56848 | CDK5/p25 | G7299 | Lipoxygenase (nonspecified subtype) | P2Y purinoceptor (nonspecified subtype) | G1111 | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase (nonspecified subtype) | G50848 | G842 | G6402 | G7442 | G5029 | G5739 | G5293 | G3274 | G142 | G4217 | G6006 | G239 | G3156 | G660 | Phospholipase A2 (nonspecified subtype) | G5291 | G1020 | PAR Receptor (nonspecified subtype) | P6463 | G187 | G79001 | G3065 | G3383 | G5742 | G23411 | G2811 | Chymotrypsin (nonspecified subtype) | G613 | G134 | G64127 | P6320 | G5024 | G3674 | G10544 | G3290 | G801 | G8600 | Integrin Receptor (nonspecified subtype) | G1859 | G2152 | G6868 | G43 | G1457 | G5030 | cGMP Phosphdiesterase (PDE) (nonspecified subtype) | G2776 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) (nonspecified subtype) | G1490 | G1803 | G19 | G729230 | G8698 | G5467 | G5743 | G135 | Acetylcholine Receptors (Nicotinic) (nAChR) (nonspecified subtype) | P6884 | G775 | Phospholipase C (nonspecified subtype) | G5290 | G554 | G350 | G6850 | G2159 | G4914 | G2321 | G255738 | P16126 | G3630 | Alcohol Dehydrogenase (nonspecified subtype) | G7046 | Tyrosine Kinase (nonspecified subtype) | Gap junction Connexin ( (nonspecified subtype) | G678 | G7534 | G231 | G5243 | G5770 | G7498 | Guanylate cyclase (nonspecified subtype) | G150 | G2147 | G5031 | G7052 | G7412 | G590 | G4524 | G3988 | G4318 | G462 | G2243 | G10747 | G6403 | G3689 | G2932 | P5762 | G5286 | Adenylate Cyclase (nonspecified subtype) | G54790 | Myosin Class II (nonspecified subtype) | G5032 | G9407 | G1066 | G9971 | P5756 | G5054 | G10630 | G51266 | G57153 | G836 | G2703 | G581 | G7113 | G4846 | Mitogen-Activated Protein Kinase (nonspecified subtype) | G1956 | Integrin alphaIIbbeta3 (fibrinogen gpIIb/IIIa) receptor | G4985 | G5287 | G5734 | G3586 | G3760 | G1360 | G3791 | G3741 | G2990 | K(ATP) Channel (nonspecified subtype) | G5340 | G5025 | G10461 | 15-Lipoxygenase (nonspecified subtype) | G7010 | G5327 | G5729 | P5662 | Vascular endothelial growth factor receptor (VEGFR) (nonspecified subtype) | G6532 | G1577 | G4620 | G80739 | G29128 | IgE Receptors (nonspecified subtype) | G7341 | G153 | G2194 | G2798 | G11251 | Phospholipase A2, Cytosolic (nonspecified subtype) | CDK1/Cyclin B | Trypsin (nonspecified subtype) | G6932 | G8654 | G51094 | G8644 | beta-Adrenoceptor (nonspecified subtype) | G64805 | G4153 | Elastase (nonspecified subtype) | G3553 | G6833 | Cysteine Protease (nonspecified subtype) | G7422 | G4739 | G8792 | G1361 | Prostanoid TP receptor (nonspecified subtype) | Serine protease (nonspecified subtype) | G3356 | P15695 | G2153 | G57007 | P11025 | G6404 | G3569 | P43029 | G3762 | G2982 | G8989 | P18298 | G4843 | P6348 | G23555 | G5140 | Kallikrein (nonspecified subtype) | G356 | G146 | G5138 | Dopamine receptor (nonspecified subtype) | CDK2/Cyclin A | G3269 | G5289 | P2X Receptor (nonspecified subtype) | G4352 | G2219 | G1559 | G3291 | Sterol O-acyltransferase (ACAT) (nonspecified subtype) | L-Type calcium channel (nonspecified subtype) | Janus Kinase (nonspecified subtype) | G185 | G7296 | G7301 | G2548 | Carboxypeptidase B (nonspecified subtype) | Leukotriene B4 receptor (LTB4-R) (nonspecified subtype) | G50508 | HTR1B | Tryptase (nonspecified subtype) | Vasopressin Receptor (nonspecified subtype) | G53637 | P22884 | G2246 | G5444 | P5757 | 5-Hydroxytryptamine Receptor 2 (5-HT2) (nonspecified subtype) | Histone deacetylase (nonspecified subtype) | G2212 | G3717 | G154 | Muscarinic Acetylcholine Receptor (mAChR) (nonspecified subtype) | Gastric H+/K+-ATPase | P13024 | G374900 | G7015 | G5345 | G3690 | Cyclooxygenase (COX) (nonspecified subtype) | alpha1-Adrenoceptor (nonspecified subtype) | Cannabinoid receptor (nonspecified subtype) | G54658 | P16740 | G79602 | Adenosine receptor (nonspecified subtype) | Inosine 5'-monophosphate dehydrogenase (IMPDH) (nonspecified subtype) | G51471 | G27035 | G348 | P46614 | G10038 | G5627 | G10855 | G201633 | G5328 | G57016 | High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7 (nonspecified protein) | G961 | Inositol 1,4,5-Trisphosphate Receptor (InsP3R) (nonspecified subtype) | G114548 | G9002 | G340061 | P6058 | G2160 | G3576 | G3818 | G51206 | G8529 | Large Conductance BK(Ca) Potassium Channel (Maxi K+ Channel) (nonspecified subtype) | P24924 | G51185 | Gap Junction Protein (nonspecified subtype) | Cyclin A (nonspecified subtype) | G6347 | G3119 | Nitric oxide synthase (NOS) (nonspecified subtype) | P34548 | G1508 | G2149 | G240 | G2923 | G3292 | Angiotensin receptor (AT) (nonspecified subtype) | G1728 | G57369 | Sphingolipid delta(4)-desaturase (nonspecified subtype) | Potassium Channels (nonspecified subtype) | P5758 | Vascular endothelial growth factors (VEGF) (nonspecified subtype) | G2155 | Endothelin receptor (nonspecified subtype) | G147 | G6915 | G4129 | G28 | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3 (PDE3) (nonspecified subtype) | G10257 | G6839 | G983 | G25 | alpha-Amylase (nonspecified subtype) | G7035 | G5294 | G2266 | G8714 | NADPH Oxidase (nonspecified subtype) | P29419 | G3162 | G290 | G5788 | P10999 | G998 | G123099 | G8445 | G8560 | G2030 | G2247 | G5972 | G22809 | G5347 | P5759 | G6774 | G5592 | G5737 | G5724 | G4953 | G5266 | Mitogen-activated protein kinase p38 (MAPK p38) (nonspecified subtype) | G5230 | G4353 | G6714 | G5144 | G387 | G7056 | G29843 | G3352 | G7124 | G3091 | Phosphodiesterase (nonspecified subtype) | G5139 | G5538 | P16091 | G246 | G3363 | P5859 | G2157 | G80036 | G5168 | G695 | G6401 | G2161 | G4215 | G6195 | G1535 | G8767 | G552 | G7157 | G327 | G6916 | G4988 | 5-Hydroxytryptamine Receptor 3 (5-HT3 receptor) (nonspecified subtype) | G3949 | G115004 | G3767 | G102465534 | G134957 | G57121 | P48131 | Phosphodiesterase IV (PDE4) (nonspecified subtype) | G1017 | G8688 | G3123 | P5575 | G948 | G1269 | G3757 | G1636 | G2859 | Cyclin B (nonspecified subtype) | G1071 | G5373 | G120892 | G1557 | G1991
The "Target / Biomarker Review Report" is a comprehensive and customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about the Target(s) / Biomarker(s) of your choice related to Thrombosis, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
Other Diseases
Thrombotic Microangiopathy | Thymoma, Malignant | Thyroid Dysgenesis | Thyroid Dyshormonogenesis | Thyroid Hormone Resistance | Thyroiditis | Thyroiditis, Autoimmune | Thyrotoxic Periodic Paralysis | Tibial Muscular Dystrophy | Tic Disorder | Tietze Syndrome | Tinea | Tinea Versicolor | Tonsillitis | Torticollis | Toxic Epidermal Necrolysis | Toxoplasmosis | Traboulsi Syndrome | Tracheal Disorders | Trachoma | Transcobalamin Deficiency | Transient Bullous Dermolysis Of The Newborn | Transthyretin-related Amyloidosis | Treacher Collins Syndrome | Tremor | Tricho-hepato-enteric Syndrome | Trichomegaly | Trichorhinophalangeal Syndrome | Trichothiodystrophy | Trichotillomania | Trichuriasis | Trigonocephaly | Trimethylaminuria | Triphalangeal Thumb-polysyndactyly Syndrome | Triple A Syndrome | Trismus-pseudocamptodactyly Syndrome | Tuberculosis | Tuberculous Meningitis | Tularemia | Tumoral Calcinosis | Turner's Syndrome | Twin-to-twin Transfusion Syndrome | Tylosis With Esophageal Cancer | Tyrosine Hydroxylase Deficiency | Tyrosinemia | Tyrosinemia Type 1 | Tyrosinemia Type 2 | Ulcerative Colitis | Unverricht-Lundborg Syndrome | Urea Cycle Disorder | Uremia | Uremic Pruritus | Ureteropelvic Junction Obstruction | Urethritis | Urofacial Syndrome | Urolithiasis | Urticaria | Usher Syndrome | Usher Syndrome Type I | Usher Syndrome Type II | Usher Syndrome Type IIC | Usher Syndrome Type III | Uterine Leiomyoma | Uveitis | Uveitis, Anterior | VACTERL Association | VACTERL/VATER Association | Vaginitis | Van Der Knaap Disease | Varices | Varicocele | Vascular Calcification | Vascular Cognitive Impairment | Vasculitis | Veno-occlusive Disease | Venous Insufficiency | Ventricular Septal Defect | Vertebrobasilar Insufficiency | Vertigo | Very Long-chain Acyl-CoA Dehydrogenase Deficiency | Vestibular Disease | VEXAS Syndrome | Vici Syndrome | Viral Meningitis | Vitamin A Deficiency | Vitamin B12 Deficiency | Vitamin D Deficiency | Vitamin K Deficiency | Vitelliform Macular Dystrophy | Vitiligo | Vitreoretinal Degeneration, Snowflake Type | Vitreoretinopathy, Proliferative | Vogt-Koyanagi-Harada Syndrome | Von Hippel-Lindau Disease | Von Willebrand Disease | Vulvovaginitis | Waardenburg Syndrome | Waardenburg Syndrome Type 1 | Waardenburg Syndrome Type 2 | Waardenburg Syndrome Type 2A | Waardenburg Syndrome Type 2E | Waardenburg Syndrome Type 4 | Waardenburg Syndrome Type 4A | Wagner Disease | WAGR Syndrome | Waldenstrom Macroglobulinemia | Walker-Warburg Syndrome | Warsaw Breakage Syndrome | Weill-Marchesani Syndrome | Werner's Syndrome | Whipple's Disease | Wieacker-Wolff Syndrome | Wiedemann-Steiner Syndrome | Williams Syndrome | Wilson's Disease | Wiskott-Aldrich Syndrome | Withdrawal Syndrome | Wolcott-Rallison Syndrome | Wolff-Parkinson-White Syndrome | Wolfram Syndrome | Wolfram Syndrome 2 | Wolman Disease | Woodhouse-Sakati Syndrome | X-linked Acrogigantism | X-linked Charcot-Marie-Tooth Disease | X-linked Creatine Transporter Deficiency | X-linked Myotubular Myopathy | X-linked Sideroblastic Anemia | Xeroderma Pigmentosum | Xeroderma Pigmentosum Variant Type | Yellow Fever | Zellweger Syndrome | Zimmermann-Laband Syndrome | Zollinger-Ellison Syndrome | Zygomycosis
